The National Toxicology Program Evaluation of Genetically Altered Mice as Predictive Models for Identifying Carcinogens

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Toxicologic pathology (Print)

• Publication date

  1998-07-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1177/019262339802600401PMID 9715504
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Remington's pharmaceutical sciences

  2016cited by this paper
• Spontaneous and Chemically Induced Proliferative Lesions in Tg.AC Transgenic and p53-Heterozygous Mice

  1998influential reference
• Association of tumor development with increased cellular proliferation and transgene overexpression, but not c-Ha-ras mutations, in v-Ha-ras transgenic Tg.AC mice.

  1996cited by this paper
• Nature and nurture: possibilities for cancer control.

  1996cited by this paper
• An estrogen receptor pathway regulates the telogen-anagen hair follicle transition and influences epidermal cell proliferation.

  1996cited by this paper
• Mechanism-based toxicology in cancer risk assessment: implications for research, regulation, and legislation.

  1996cited by this paper
• Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens.

  1996cited by this paper
• IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

  1995cited by this paper
• Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models.

  1995cited by this paper
• Data analysis: statistical analysis and use of historical control data.

  1995cited by this paper
• Genetic toxicology: current status of methods of carcinogen identification.

  1993cited by this paper
• Spontaneous and carcinogen–induced tumorigenesis in p53–deficient mice

  1993cited by this paper
• Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

  1992cited by this paper
• Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals

  1992influential reference
• v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid.

  1990cited by this paper
• Salmonella mutagenicity tests: IV. Results from the testing of 300 chemicals

  1988cited by this paper
• Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42.

  1987cited by this paper
• Salmonella mutagenicity test results for 250 chemicals.

  1983influential reference
• National Toxicology Program

  1981cited by this paper
• Bioassay of p-Anisidine Hydrochloride for Possible Carcinogenicity (CAS No. 20265-97-8).

  1978cited by this paper
• Estrogen receptor in the mouse skin.

  1978cited by this paper

• Toxicological properties of glycidyl esters

  2022cites this paper
• The 2-year rodent bioassay in drug and chemical carcinogenicity testing: Panorama of its concordance, utility, configuration, and provisional regulatory role.

  2021cites this paper
• Carcinogenicity and Genotoxicity

  2015cites this paper
• Report on Carcinogens Monograph on Pentachlorophenol and By-products of Its Synthesis

  2014cites this paper
• Alternative methods for regulatory toxicology – a state-of-the-art review

  2014cites this paper
• 14 – Pathology Issues in the Design of Toxicology Studies

  2013cites this paper
• The use of genetically modified mice in cancer risk assessment: Challenges and limitations

  2013influential citation
• Health risks from dioxin and related compounds

  2013cites this paper
• Comparative dermal toxicity of dicyclohexylcarbodiimide and diisopropylcarbodiimide in rodents

  2012influential citation
• Dose-dependent mesothelioma induction by intraperitoneal administration of multi-wall carbon nanotubes in p53 heterozygous mice

  2012cites this paper
• Reduction in the Number of Animals and the Evaluation Period for the Positive Control Group in Tg.rasH2 Short-Term Carcinogenicity Studies

  2012cites this paper
• ENVIRONMENTAL SOLUTIONS GROUP, LLC

  2011cites this paper
• Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010

  2011cites this paper
• Proceedings of the 2009 National Toxicology Program Satellite Symposium

  2010influential citation
• Spontaneous Acute Tumor Lysis Syndrome as a Cause of Early Deaths in Short-Term Carcinogenicity Studies Using p53 +/– Mice

  2010cites this paper
• An Industry Perspective on the Utility of Short-Term Carcinogenicity Testing in Transgenic Mice in Pharmaceutical Development

  2010cites this paper
• Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective

  2010cites this paper
• Aflatoxin B1 and/or Hepatitis B Virus Induced Tumor Spectrum in a Genetically Engineered Hepatitis B Virus Expression and Trp53 Haploinsufficient Mouse Model System for Hepatocarcinogenesis

  2009cites this paper
• Evaluation of dichloroacetic acid for carcinogenicity in genetically modified Tg.AC hemizygous and p53 haploinsufficient mice.

  2009cites this paper
• Annual Review of Cosmetic Ingredient Safety Assessments: 2005/20061

  2008cites this paper
• Genetically Engineered Animals

  2007cites this paper
• Eplerenone: a selective aldosterone receptor antagonist (SARA).

  2006cites this paper
• Final Amended Report on the Safety Assessment of Oxyquinoline and Oxyquinoline Sulfate as Used in Cosmetics1

  2006cites this paper
• Topical Application of Representative Multifunctional Acrylates Produced Proliferative and Inflammatory Lesions in F344/N Rats and B6C3F1 Mice, and Squamous Cell Neoplasms in Tg.AC Mice

  2005influential citation
• Conversion of tris(8-quinolinolato-N1, O8) aluminum to 8-hydroxyquinoline and activity in bacterial reverse mutation assays.

  2005cites this paper
• The results of five coded compounds: genistein, metaproterenol, rotenone, p-anisidine and resorcinol tested in the pH 6.7 Syrian hamster embryo cell morphological transformation assay.

  2005cites this paper
• Historical perspective of the cancer bioassay.

  2005cites this paper
• Oral and dermal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces cutaneous papillomas and squamous cell carcinomas in female hemizygous Tg.AC transgenic mice.

  2004cites this paper
• 6. CARCINOGENICITY OF TCDD IN ANIMALS - Exposure and Human Health Reassessment of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds - Part II

  2004cites this paper
• Transgenic mice as alternatives in carcinogenicity testing: current status

  2004influential citation
• 13 – New Animal Models in Toxicology

  2002cites this paper
• Evaluation of the Tg.AC Transgenic Mouse Assay for Testing the Human Carcinogenic Potential of Pharmaceuticals—Practical Pointers, Mechanistic Clues, and New Questions

  2002cites this paper
• Identification of mammary carcinogens in rodent bioassays

  2002cites this paper
• Genetic interaction between the unstable v-Ha-RAS transgene (Tg.AC) and the murine Werner syndrome gene: transgene instability and tumorigenesis

  2002cites this paper
• Use of Genetically Engineered Mice in Drug Discovery and Development: Wielding Occam's Razor to Prune the Product Portfolio

  2002cites this paper
• The Trp53 Hemizygous Mouse in Pharmaceutical Development: Points to Consider for Pathologists

  2002cites this paper
• An EU perspective on the use of in vitro methods in regulatory pharmaceutical toxicology.

  2002cites this paper
• The role of transgenic mouse models in carcinogen identification.

  2002influential citation
• The Nature of the Heterozygous Trp53 Knockout Model for Identifi cation of Mutagenic Carcinogens

  2001cites this paper
• The Tg.AC (v-Ha-ras) Transgenic Mouse: Nature of the Model

  2001influential citation
• Bioassay of mannitol and caprolactam and assessment of response to diethylnitrosamine in heterozygous p53-deficient (+/-) and wild type (+/+) mice

  2001cites this paper
• Analysis for loss of heterozygosity (LOH) of p53 allele in tumors derived from p53+/− and CD‐1 mice following repeated subcutaneous injections of solutions containing antioxidants

  2001cites this paper
• Induction and time-dependent accumulation of micronuclei in peripheral blood of transgenic p53+/- mice, Tg.AC (v-Ha-ras) and parental wild-type (C57BL/6 and FVB/N) mice exposed to benzene by inhalation.

  2001cites this paper
• Tg.AC Genetically Altered Mouse: Assay Working Group Overview of Available Data

  2001cites this paper
• Comparative xenobiotic metabolism between Tg.AC and p53+/- genetically altered mice and their respective wild types.

  2001cites this paper
• Phenobarbitone-induced liver response in wild type and in p53 deficient mice.

  2001cites this paper
• p53 +/- Hemizygous Knockout Mouse: Overview of Available Data

  2001cites this paper
• Xpa and Xpa/p53+/- Knockout Mice: Overview of Available Data

  2001cites this paper
• Oncogenes, Anti-Oncogenes, and Genetic Regulators of Vascular Development

  2001cites this paper
• Appendix III

  2001cites this paper
• Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays.

  2000cites this paper
• Hepatic drug metabolizing enzymes induced by clofibrate in rasH2 mice.

  2000cites this paper
• Statistical analysis of skin tumor data from Tg.AC mouse bioassays.

  2000cites this paper
• Mice Heterozygous for a Brca 1 or Brca 2 Mutation Display Distinct Mammary Gland and Ovarian Phenotypes in Response to Diethylstilbestrol 1

  2000cites this paper
• Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.

  2000cites this paper
• Manipulating the germline: its impact on the study of carcinogenesis.

  2000cites this paper
• The Use of Genetically Modified Animals in Carcinogenicity Bioassays

  2000cites this paper
• Interlaboratory comparison of the CB6F1-Tg rasH2 rapid carcinogenicity testing model.

  2000cites this paper
• Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol.

  2000influential citation
• Assessment of immunosuppressant drug carcinogenicity: standard and alternative animal models

  2000cites this paper
• Evaluation of cytotoxicity, cell proliferation, and genotoxicity induced by p-cresidine in hetero- and nullizygous transgenic p53 mice.

  2000cites this paper
• Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment

  2000cites this paper
• Lack of Carcinogenic Sensitivity of the Glandular Stomach in Heterozygous p53 Knockout Mice Given N-Methyl-N-Nitrosourea in their Drinking Water for 26 Weeks.

  2000cites this paper
• Responses of Transgenic Mouse Lines p 53 1 / 2 and Tg z AC to Agents Tested in Conventional Carcinogenicity Bioassays

  2000cites this paper
• Evaluation of in vitro reporter gene induction assays for use in a rapid prescreen for compound selection to test specificity in the Tg.AC mouse short-term carcinogenicity assay.

  2000cites this paper
• V-Ha-ras gene expression in liver and kidney of transgenic Tg.AC mice following chemically induced tissue injury.

  1999cites this paper
• Development of a transgenic mouse model for carcinogenesis bioassays: evaluation of chemically induced skin tumors in Tg.AC mice.

  1999cites this paper
• Spontaneous and Chemically Induced Proliferative Lesions in Tg.AC Transgenic and p53-Heterozygous Mice

  1998cites this paper
• Phenobarbital Does Not Promote Hepatic Tumorigenesis in a Twenty-Six-Week Bioassay in p53 Heterozygous Mice

  1998cites this paper
• The Potential of Genetically Altered Mice as Animal Models for Carcinogen Identification

  1998cites this paper